Indication
For the treatment of cystic fibrosis (CF) in patients aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.
Medicine details
- Medicine name:
- lumacaftor-ivacaftor (Orkambi)
- SMC ID:
- SMC2182
- Pharmaceutical company
- Vertex Pharmaceuticals Ltd
- BNF chapter
- Submission type
- Full
- Status
- Publication due date:
- 12 August 2019
- SMC meeting date:
- 02 July 2019
- Patient group submission deadline:
- 06 May 2019